Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the most promising penny stocks under $5. On August 8, Wells Fargo lowered the firm’s price target on Iovance Biotherapeutics to $14 from $18, while keeping an Overweight rating on the shares. While the stock reacted negatively after-hours to Q2 2025 results, the firm pointed out that the revenue miss was mainly due to IL-2, with Amtagvi meeting consensus.
Iovance Biotherapeutics’ total revenue for Q2 was $60 million, which was a 93% increase year-over-year and a 22% sequential growth. This was driven by the company’s cell therapy, Amtagvi, which generated $54.1 million in sales. Proleukin, another of the company’s products, contributed an additional $5.9 million in product revenue.
A medical staff in white coats monitoring the progress of cancer immunotherapy trials.
The company successfully treated over 100 patients with its Amtagvi therapy for advanced melanoma, a first for the company in a single quarter. Real-world data from authorized treatment centers showed a nearly 49% response rate among patients treated with Amtagvi, with the response rate rising to 61% in patients who had received two or fewer prior lines of therapy.
Iovance Biotherapeutics Inc. is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies using autologous tumor-infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers in the US.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
